{"name":"Ablynx, a Sanofi company","slug":"ablynx-a-sanofi-company","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ALX-0061","genericName":"ALX-0061","slug":"alx-0061","indication":"Psoriasis","status":"phase_2"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"ALX-0081","genericName":"ALX-0081","slug":"alx-0081","indication":"Acquired thrombotic thrombocytopenic purpura (aTTP)","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"ATN-103","genericName":"ATN-103","slug":"atn-103","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"ALX-0061","genericName":"ALX-0061","slug":"alx-0061","phase":"phase_2","mechanism":"ALX-0061 is a nanobody targeting IL-17A and IL-17F, which are pro-inflammatory cytokines involved in autoimmune diseases.","indications":["Psoriasis","Ankylosing spondylitis"],"catalyst":""},{"name":"ALX-0081","genericName":"ALX-0081","slug":"alx-0081","phase":"phase_2","mechanism":"ALX-0081 is a nanobody that specifically targets von Willebrand factor (vWF), reducing its activity and preventing platelet aggregation.","indications":["Acquired thrombotic thrombocytopenic purpura (aTTP)"],"catalyst":""},{"name":"ATN-103","genericName":"ATN-103","slug":"atn-103","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxORV9JMjVwbFBDeWVGanRuLWgxUWs5enQ1VXFScTFic0I4NXJ4V0xEOGNFbk9pNzJVYUVPanYxS2FTYmhkMEtFZUwyN0N2Tm5IMVZTdHBtMUNVTFN5ZmhJUnBoeU9QaGFoVGFBN1N6MmQzTlFVVWY1ZUctc1lNcjcyag?oc=5","date":"2025-08-26","type":"pipeline","source":"Sanofi","summary":"NANOBODY® Technology Platform - Sanofi","headline":"NANOBODY® Technology Platform","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQSkJBT3d1VGRMZkRyODdDTmd1WWdOWkxud05oeDFYRjFvZlE3X1ZWb2hDMXU5WWtaZkRRZkxvRUs4M1N0cjJFZlJLMTFwZmlNTFpRX3AweFU2NWpIcDR1TVFiN2VMREcwd0RZXzJzdzZ6RGlXUExST0VBTHpiQnBldldfV0tTRHVVRFh6cEk0N3piMlhV?oc=5","date":"2023-04-27","type":"deal","source":"BioSpace","summary":"Sanofi Cleans House, Cuts Assets from Principia and Ablynx Buyouts - BioSpace","headline":"Sanofi Cleans House, Cuts Assets from Principia and Ablynx Buyouts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE10UHBSZDN1dTJ0QlVGb21pcmJWY1d1U0cxVng1VmNRczU4ak1hRi15RjFqZ0hlMzlINEstbFFLVGcwVUNaRzFrSGh0TzQ0V2JFZnEtaXBQdlVEOFhGTnN5UW9WQ1NKQXhmMkNNeXNFZU9YbjZLanBMMQ?oc=5","date":"2021-08-11","type":"deal","source":"Labiotech.eu","summary":"Another One Gets Snapped Up: Ablynx has been Acquired by Sanofi for €3.9B - Labiotech.eu","headline":"Another One Gets Snapped Up: Ablynx has been Acquired by Sanofi for €3.9B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPb3NjS3BlRk85N0lscjJ0SV9qeUtlVFVLMzBYNkoyb2tzSmlrbmtGQldhMXl4bGN1R3pCRDZaUjQxUGYtRUNvRnlBN2plNnVXZ3p0UllqY01kTHhLeUJ2ajFUd3pFTXlfd05adU9oY2pMTjNsdWxLbHp3YTUtRkNKa21raXV0eEpfUS12dEhNc2pYOGxuUmxmV1ZMbXRibmNyMXhvVG4yT2wyUDhOOG1Da3Rnd1pXUmtJMGg2RWNXY0NhWDVDZjJJ?oc=5","date":"2021-07-15","type":"deal","source":"Business Wire","summary":"LabGenius Announces Research Collaboration With Ablynx, a Sanofi Company - Business Wire","headline":"LabGenius Announces Research Collaboration With Ablynx, a Sanofi Company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQZnZfdERvWFUzd25iS0oyRWJyenhwNmF1VDhJXzdhQlRuYVRiNnhSa1Y3bE9kVGZLZmVlZnRXbHFaWEQzSDg3Z2pfOEs0TUxLSVlJSEg1ejVrdUZxWXdDRWNMd2VtWHVEVEZ5Zm9CWjhON25lQTNlS3ZoQnBqMEwtZm5UNjMxZFQ4MVV3aG8xQmg3U0Y3eVVJMHhobTRPQ0RwQzUtSkNYVkpPUG50UlVrS1BVMjJ0RTFVZEE?oc=5","date":"2018-09-04","type":"pipeline","source":"Fierce Pharma","summary":"Sanofi’s first Ablynx drug, rare blood disorder treatment Cablivi, clears final EU hurdle - Fierce Pharma","headline":"Sanofi’s first Ablynx drug, rare blood disorder treatment Cablivi, clears final EU hurdle","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPa2JoYjhhTWJpcHdXaVJJOXlSSkl3eXotUW1ldHB4UUZlQmJ4RFg4Ny1MVzltSVhQTTdWVE9TOHd2Rk9HZmxCZGJZQUhjYjRDRm9uRGxIbWRPMmJjSHJrLU54cnBycW5XZjIxRHZrWFkyQmk0SFluYjhyV2tGX0kzRGFQUHVrTXJDa3hGakNMb09reWdRR0Nn?oc=5","date":"2018-06-19","type":"pipeline","source":"BioProcess International","summary":"Sanofi: ‘Ablynx Nanobody Tech Will Fuel Innovation’ - BioProcess International","headline":"Sanofi: ‘Ablynx Nanobody Tech Will Fuel Innovation’","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE5seHBTd0x5RmFlNklVWXRoUy1DempneElNTy1RMGZ2NzBMSDRwU09HLVdJZHlvWS0zcUZ0bk05ZW1RR0VYaERBVWMyYm1wTmlsUnlFakdOVDdVYzh3YS1UeEIyTDc0ZjZqNHZNMmRTbHppUDhNSWFoNWFWZw?oc=5","date":"2018-02-05","type":"pipeline","source":"cen.acs.org","summary":"Sanofi to boost rare blood disease pipeline with Ablynx acquisition - cen.acs.org","headline":"Sanofi to boost rare blood disease pipeline with Ablynx acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxPQU5hWDMyZXhoN2JVRVNPb0lEbW4wNGRPN1dTZWVBY3Z3SkllQzQ1T3FMLVBYMTN5TlZKU2VyeEhUMEp4b3BKUnlLa2ZPZ3BXNzJuLWgxa2dSMG9fRWJkZkhaWTlXbEEzZDFaa1FqQ0pkQ0tmZm0zajR4bWJFNWhSd2NlVUtfZw?oc=5","date":"2018-02-01","type":"pipeline","source":"Chemistry World","summary":"Sanofi enters M&A bonanza - Chemistry World","headline":"Sanofi enters M&A bonanza","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPZDc1SnUzZmYtZ1UyMHNEZmNtUjhjaFBESFVxTUJKM2hNYVowMFJSTFdBZFRjbU84TzZuZTA0Y3VQMEJGNlFTckk5Q1VUdnROT1FhaXJUbDg5YXM1cXpzSW1laGMySmJfOVEzNVpDenJQRTNrc1VndkdHdEVLbFVmbkhlc1B5ZG4xdGJxNjNEZERjVWp2RzhB?oc=5","date":"2018-01-29","type":"deal","source":"Fierce Biotech","summary":"Sanofi inks €3.9B Ablynx buyout to pip Novo in M&A fight - Fierce Biotech","headline":"Sanofi inks €3.9B Ablynx buyout to pip Novo in M&A fight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQcnE3SXRhYngwZGVjcEpJX3lSVGV6WVYyNllxV0EyZnpnSEd1YUg3bzZoMlZMTlM3d09CUWJKbVRLWk9xSHVva3lXZWFxNUtJNjFHRWcxR3NCS2FfZTdsUlZPV3JkcjlvMnpiUWRGNzlvVmYwMzhoRHc2aUlUUVNCdC03TE1CSHR2X0NvUVFLbl9kVXhvdFpnaEZB?oc=5","date":"2018-01-29","type":"pipeline","source":"BioPharma Dive","summary":"Sanofi snaps up Ablynx after underwhelming Novo bid - BioPharma Dive","headline":"Sanofi snaps up Ablynx after underwhelming Novo bid","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOZjdkbTU4cVNOaFZnakVSWjM1MHlhdThSMFh2eTBiU0dUam1YU05COFQzc2hZVFM4MV9ocWxiRUFxbVdoRlpOb1NHOWtuQm5YTXV4SzFKVzhzMHJENjBMem9XN1k3bWN0QWx5aVpkTTNuM2t4TDlSNDlTODlPT1Y1WHc1RUtaUVI3Yjl3YktSRGdGZkdVVUdXdFZRVkJsS19jYXNJY1gzM1JKT2VmZzlVQXVGM0w1enRJb0E?oc=5","date":"2018-01-29","type":"deal","source":"Reuters","summary":"Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom - Reuters","headline":"Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTFBMQ2FzbjNEbnRQVWdfVm1hVmcwXzhSR2dKM19udTZoVnZfdnNRLUJHcmMtRllOdzBLaXlNZEZGb1U2SmFJblpJXzA3dHkwNldDOGFfUk5ZSzZSV0ZLZnlBMWkycmdBbTVvNWRSZVFTRXE?oc=5","date":"2018-01-29","type":"deal","source":"Fortune","summary":"Why Sanofi Is Buying Belgian Biotech Company Ablynx for Nearly $5 Billion - Fortune","headline":"Why Sanofi Is Buying Belgian Biotech Company Ablynx for Nearly $5 Billion","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":3},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}